1 FIRST MEETING OF COORDINATION COMMITTEE OF EU ‘BUDGET SUPPORT FOR EMPLOYMENT REFORM IN MONGOLIA’ WWW.MONTSAME.MN PUBLISHED:2021/04/19      2 THE REALITIES OF CLIMATE CHANGE ARE PUSHING BIG BUSINESSES TO FOCUS ON SUSTAINABILITY WWW.CNN.COM PUBLISHED:2021/04/19      3 TWO MEN KILLED IN TESLA CAR CRASH 'WITHOUT DRIVER' IN SEAT WWW.BBC.COM PUBLISHED:2021/04/19      4 MONGOLIA STARTS USING COVID-19 EXPOSURE NOTIFICATION - IOS, ANDROID TRACKING FEATURE WWW.MONTSAME.MN PUBLISHED:2021/04/19      5 CHINA SAYS IT HAS NO PLANS TO OUST US DOLLAR WITH DIGITAL YUAN WWW.RT.COM PUBLISHED:2021/04/19      6 RIO TINTO COPPER CHIEF QUIZZED ON PAYMENTS TO MONGOLIAN CITIZENS WWW.FT.COM PUBLISHED:2021/04/19      7 STEPPE FIRE IN EASTERN MONGOLIA COMPLETELY EXTINGUISHED WWW.XINHUANET.COM PUBLISHED:2021/04/19      8 MONGOLIA CONFIRMED 889 NEW CASES OF COVID-19 WWW.AKIPRESS.COM PUBLISHED:2021/04/19      9 CHINA'S ECONOMY GROWS BY A RECORD 18.3% IN THE FIRST QUARTER WWW.CNN.COM PUBLISHED:2021/04/18      10 IRON ORE PRICE HITS 10-YEAR HIGH ON RISING STEEL DEMAND WWW.MINING.COM PUBLISHED:2021/04/18      МОНГОЛ УЛС ӨНГӨРСӨН САРД 121 УЛСТАЙ ХУДАЛДАА ХИЙЖЭЭ WWW.MONTSAME.MN НИЙТЭЛСЭН:2021/04/19     “ZEUS” БАГ ТЭРБУМ ТӨГРӨГИЙН ШАГНАЛЫН САНТАЙ ТЭМЦЭЭНД ОРОЛЦОХ ЭРХЭЭ АВЧЭЭ WWW.EAGLE.MN НИЙТЭЛСЭН:2021/04/19     МОНГОЛООС БНХАУ-Д НИЙЛҮҮЛЖ БУЙ КОКСЖИХ НҮҮРСНИЙ ХЭМЖЭЭ БАГА ХЭВЭЭР БАЙНА WWW.BLOOMBERGTV.MN НИЙТЭЛСЭН:2021/04/19     ҮСХ: I УЛИРАЛД 189.9 МЯНГАН ИРГЭН ХИЛЭЭР НЭВТЭРСЭН НЬ ӨМНӨХ ОНЫ МӨН ҮЕЭС 65.6 ХУВИАР БУУРСАН ДҮН БОЛЛОО WWW.BLOOMBERGTV.MN НИЙТЭЛСЭН:2021/04/19     НЭГДҮГЭЭР УЛИРАЛД УЛСЫН ТӨСВИЙН АЛДАГДАЛ ₮96 ТЭРБУМД ХҮРЧЭЭ WWW.IKON.MN НИЙТЭЛСЭН:2021/04/19     МОНГОЛ УЛС САЯ ХҮН АМД НООГДОХ НЭГ ӨДӨРТ ИЛЭРСЭН COVID-19 ХАЛДВАРЫН ТОХИОЛДЛООР БҮС НУТАГТАА ТЭРГҮҮЛЖ БАЙНА WWW.IKON.MN НИЙТЭЛСЭН:2021/04/19     АЧАА ТЭЭВЭР ӨСӨЖ, ЗОРЧИГЧ ТЭЭВЭР БУУРЧЭЭ WWW.EAGLE.MN НИЙТЭЛСЭН:2021/04/19     УУЛ УУРХАЙН САЛБАРТ ӨСӨЛТ АЖИГЛАГДАНА WWW.EAGLE.MN НИЙТЭЛСЭН:2021/04/19     ХИЛИЙН БООМТЫН ҮЙЛ АЖИЛЛАГАА ХЭВИЙН БАЙНА WWW.EAGLE.MN НИЙТЭЛСЭН:2021/04/18     ГЕГ: 2021 ОНЫ I УЛИРАЛД НИЙТ 15 МЯНГА 99 АВТОМАШИН ИМПОРТОЛСОН WWW.BLOOMBERGTV.MN НИЙТЭЛСЭН:2021/04/18    

Johnson & Johnson's one-shot COVID-19 vaccine effective and safe: FDA staff www.reuters.com

(Reuters) - Johnson & Johnson’s one-shot COVID-19 vaccine appeared safe and effective in trials, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use.
Slideshow ( 2 images )
The FDA’s panel of independent experts meets on Friday to decide whether to approve the shot. While it is not bound to follow the advice of its experts, the FDA usually does and has authorized vaccines from Pfizer and Moderna.
J&J said in documents submitted to the FDA that its data suggested its vaccine was effective at preventing asymptomatic infections. It said that in a preliminary analysis of its trial, it found 16 cases of asymptomatic cases in the placebo group versus two in the vaccine group, or an 88% efficacy rate.
While asymptomatic infection was not the primary goal of the trial, which studied the vaccine’s ability to stop moderate to severe COVID-19, the reduction of asymptomatic cases implies the shot can also cut transmission of the disease.
J&J’s vaccine was 66% effective in preventing COVID-19 against multiple variants in a global trial involving nearly 44,000 people, the company said last month.
Its effectiveness varied from 72% in the United States to 66% in Latin America and 57% in South Africa, where a new variant has spread, though the vaccine was 85% effective overall in stopping severe cases of the disease.
The vaccine was effective in reducing the risk of COVID-19 and preventing PCR-test confirmed COVID-19 at least 14 days after vaccination, the FDA said in its briefing documents.
Fourteen days after injection, only two vaccine recipients developed COVID-19 severe enough to need medical intervention, compared with 14 in the placebo group. After 28 days, no vaccine recipients developed COVID severe enough to require medical intervention whereas seven in the placebo group did.
Three vaccine recipients had severe side effects in the trial that were likely related to the vaccine, but the FDA said its analysis did not raise any specific safety concerns that would preclude issuance of an emergency use authorization.
The FDA said the most common solicited adverse reactions were injection site pain at 48.6%, headache at 39%, fatigue at 38.2% and myalgia at 33.2%. Other side effects included a fever in 9% of participants and a high fever in 0.2% of those who received the vaccine.
The regulator said one case of pericarditis, a heart disease, may have been caused by the vaccine. It said cases of a rare disorder, Guillain-Barre Syndrome, were unlikely to be related to the shot though data was insufficient to determine whether or not the vaccine had caused these side effects.
J&J had not previously released details of its clinical trial data beyond efficacy rates.
Reporting by Manas Mishra in Bengaluru; Mike Erman, Caroline Humer and Rebecca Spalding; Editing by Bernard Orr and David Clarke


Published Date:2021-02-24